Cryoglobulinaemia

[1] [1]

Think of the clinical syndrome before the laboratory label. A patient may have palpable purpura, neuropathy or glomerulonephritis from immune-complex vasculitis, or digital ischaemia and hyperviscosity from an occlusive monoclonal protein. The shared laboratory property is reversible precipitation below 37°C.[1][2]

A positive cryoglobulin test does not by itself prove symptomatic disease. The examiner wants you to connect the cryoglobulin type, the organ pattern and the underlying infection, autoimmune disease or haematological clone.[1]

Classification — Brouet explains the mechanism

[1] [3] [10] [11]

Epidemiology and Causes — ask what drives the protein

Do not quote one global HCV percentage without its era and denominator. HCV was historically the principal cause of mixed cryoglobulinaemia in many cohorts. After effective antiviral treatment, contemporary reviews describe a larger relative contribution from autoimmune disease, haematological malignancy and cases with no identified cause. The mix therefore varies by geography, HCV prevalence and treatment access.[2][3]

• Type I: monoclonal gammopathy of undetermined significance, lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, multiple myeloma and other clonal B-cell or plasma-cell disorders.
• Mixed Types II/III: chronic HCV remains an essential cause to test for; HBV, HIV, autoimmune disease and haematological malignancy are other recognised associations.
• Essential cryoglobulinaemia: no associated disease is found after an appropriate search; this is a diagnosis of exclusion.[1][2]

Pathophysiology — occlusion versus immune complexes

Type I: a cryoprotein blocks flow

A single monoclonal immunoglobulin precipitates or aggregates, especially in cooler peripheral vessels. The result is predominantly an occlusive vasculopathy: Raynaud phenomenon, livedo, ulcers, necrosis, digital ischaemia or, with a large circulating protein burden, hyperviscosity symptoms. Inflammatory skin or renal manifestations can occur, so “no purpura, no nephritis and normal complement” is unsafe exam shorthand.[1][10][11]

Types II and III: rheumatoid factor builds an immune complex

IgM with rheumatoid-factor activity binds the Fc portion of IgG. The complexes deposit in small vessels and activate the classical complement pathway. C4 is commonly consumed disproportionately; neutrophil recruitment and vessel-wall injury produce leukocytoclastic vasculitis. Type II uses a monoclonal IgM rheumatoid factor, whereas Type III uses a polyclonal IgM rheumatoid factor.[1][3]

Chronic HCV can sustain B-cell expansion and pathogenic IgM-rheumatoid-factor production. Removing the viral drive with direct-acting antivirals is fundamental, but an established B-cell clone or immune process may persist after sustained virological response.[1][4][6]

Clinical Presentation — meet the two patterns

Mixed cryoglobulinaemia

Meltzer's triad is purpura, arthralgia and weakness. It is memorable, not mandatory. Palpable dependent purpura is the classic skin lesion; peripheral neuropathy and membranoproliferative-pattern glomerulonephritis are the major neurological and renal associations.[1][3]

• Skin: recurrent palpable purpura, ulcers or necrosis.
• Joints and general: arthralgia, fatigue and weakness.
• Nerves: painful sensory or sensorimotor neuropathy; mononeuritis multiplex may occur.
• Kidneys: haematuria, proteinuria, hypertension, active sediment or impaired renal function.
• Severe systemic disease: gastrointestinal ischaemia, pulmonary involvement or other multiorgan vasculitis is uncommon but dangerous.[1][8]

Type I cryoglobulinaemia

Look for cold-dependent acrocyanosis, Raynaud phenomenon, livedo, ulcers, necrosis and digital ischaemia. Headache, visual change, neurological symptoms and mucosal bleeding suggest hyperviscosity. Skin, neurological and renal involvement were all present in a modern Type I cohort, which is why a purpuric or renal presentation cannot be used as an absolute exclusion.[10]

[1] [11]

Differential Diagnosis — separate a mimic from a cause

The bedside round — three questions

Ask whether the tempo is indolent, severe or immediately life-threatening. Examine the full skin surface and digits; document ulcers or necrosis; perform a peripheral neurological examination; measure blood pressure; assess urine output and volume status; and examine the fundi when hyperviscosity is suspected.[1][8]

Then search deliberately for the cause: HCV/HBV/HIV risk, sicca or other autoimmune features, constitutional or haematological symptoms, monoclonal gammopathy history and recent infection. The clinical syndrome and its cause determine treatment more than the cryoglobulin level alone.[1][2]

Investigations — the warm sample is the exam trap

Confirm the cryoglobulin correctly

Speak to the laboratory before collection. Use a pre-warmed collection system and maintain whole blood at 37°C through clotting, centrifugation and serum separation. Only after serum has been separated is it cooled according to the laboratory's validated protocol; the precipitate must redissolve on warming. Premature cooling can lose cryoprecipitate during transport or in the clot and produce a false-negative result.[9]

[1] [3]

Type the protein, stage the organs, find the cause

• Type the cryoglobulin: immunofixation of the cryoprecipitate distinguishes monoclonal from mixed patterns; serum protein electrophoresis, immunofixation and free light chains look for a clone.
• Support mixed disease: C4 is often markedly low, C3 may be normal or low, and rheumatoid factor is often positive.
• Find infection: HCV antibody followed by HCV RNA for current infection; HBV serology with HBV DNA when indicated; HIV testing.
• Stage injury: full blood count, renal and liver function, urinalysis, urine protein quantification and neurological testing as clinically indicated.
• Biopsy active disease: a fresh skin lesion may show leukocytoclastic vasculitis; renal biopsy commonly shows an immune-complex membranoproliferative pattern and also excludes pauci-immune or other disease.[1][2][3]

[9]

Management — Resuscitation

Type I hyperviscosity or critical occlusion

Urgent therapeutic plasma exchange can rapidly remove the circulating cryoprotein in symptomatic hyperviscosity. Keep the patient warm, support perfusion, obtain urgent haematology input and start clone-directed therapy. Rituximab is relevant to a CD20-positive B-cell clone; it is not a universal treatment for plasma-cell myeloma.[1][12]

Life-threatening mixed cryoglobulinaemia

Rapid renal decline, gastrointestinal ischaemia, pulmonary haemorrhage or other critical multiorgan disease requires urgent multidisciplinary care. Consensus recommendations place therapeutic plasma exchange as first-line for life-threatening mixed cryoglobulinaemia; high-dose pulsed glucocorticoids may be used for rapid inflammatory control, generally with plasma exchange. Rituximab is considered for ulcers, neuropathy or glomerulonephritis and for life-threatening disease persisting after plasma exchange. Start HCV antiviral therapy as soon as the patient is stable enough.[8]

[8] [12] [1] [6] [7] [8] [12]

Prognosis turns on the Brouet type, the underlying cause, the severity of organ involvement, and the response to treatment.[1]

DAAs reliably eradicate HCV in more than 95% of treated patients, but virological cure and immune or clinical remission are not synonymous. A systematic review found complete clinical responses ranging from 63.7% to 90.2%, relapse in 4% to 18%, and persistent B-cell clones in 31% to 40% after HCV cure. Persistent or recurrent organ-active disease requires reassessment for a surviving B-cell clone and severity-directed treatment.[4]

Rituximab: a specialist-selected regimen

Rituximab is supported for active mixed cryoglobulinaemic ulcers, neuropathy and glomerulonephritis. Regimens reported in the GISC evidence review include 375 mg/m² intravenously weekly for four doses, 1 g intravenously on days 1 and 15, and, in selected patients, 250 mg/m² intravenously weekly for two doses. Choice is not interchangeable or automatic: it depends on severity, comorbidity, infection status and specialist protocol. Screen for HBV and manage reactivation risk according to serostatus and current guidance.[7]

Glucocorticoids can suppress active vasculitis but have no maintenance role; taper once disease control permits. Evidence for automatically combining cyclophosphamide with plasma exchange is limited and inconclusive, and rituximab has replaced cyclophosphamide in many settings.[8][12]

Specific Subtypes and Scenarios

• Type I: define the clone and treat it; use urgent plasma exchange for symptomatic hyperviscosity or critical cryoprotein-mediated occlusion.
• HCV-associated mixed disease: start current DAA therapy; reassess persistent vasculitis after sustained virological response rather than assuming cure.
• Non-HCV mixed disease: treat the autoimmune, infectious or haematological driver and use rituximab when organ-active disease warrants it.
• Neuropathy: distinguish active progression from fixed axonal damage; early control may prevent progression, while established deficits may recover incompletely.
• Glomerulonephritis: biopsy when it will distinguish the lesion or change treatment; coordinate nephrology, infection and immunosuppression decisions.[1][4][7][8]

Complications and Pitfalls

• Chronic kidney disease, fixed neuropathy, skin ulceration or necrosis, digital loss and gastrointestinal ischaemia can follow uncontrolled disease.
• Infection is an important treatment complication, especially when glucocorticoids, B-cell depletion or other immunosuppression is used.
• Poor warm handling is a major cause of false-negative cryoglobulin tests.
• A real PMID can still be the wrong source: the authorless PMID 30072792 is a separate PrimeView record, not the Roccatello et al. Primer at PMID 30072738.
• A sustained virological response does not guarantee disappearance of cryoglobulins, B-cell clones or organ-active vasculitis.[4][8][9]

Prognosis and Disposition

Prognosis is driven by the underlying disease and the extent of vasculitis-associated organ damage. Admit patients with hyperviscosity, critical ischaemia, rapidly declining renal function, gastrointestinal or pulmonary involvement, or a rapidly progressive neurological deficit. Stable skin-limited disease may be managed as an outpatient only when organ disease has been assessed and timely specialist follow-up is secure.[1][8]

After HCV cure, follow the patient, not just the RNA result: recurrence of purpura, neuropathic symptoms, urinary abnormalities or systemic features should prompt reassessment. Persistent cryoglobulins or a B-cell clone can accompany incomplete or relapsing clinical response.[4][6]

Special populations — pregnancy, elderly, immunocompromised

Evidence for pregnancy and paediatric cryoglobulinaemia is limited, so do not extrapolate an adult treatment bundle. Confirm the cause and organ severity, then coordinate maternal–fetal medicine or paediatric specialists with haematology, rheumatology, nephrology, hepatology and transfusion medicine as needed. Drug and antiviral choices follow the relevant current population-specific guidance rather than a universal cryoglobulinaemia regimen.[1][8]

In older or immunocompromised patients, actively exclude a haematological clone and infection before escalating immunosuppression. In any patient receiving rituximab, HBV screening and reactivation-risk management are mandatory parts of treatment planning.[2][7]

[2] [1]

The historical VASCUVALDIC study was a prospective uncontrolled 24-patient clinical cohort, not a randomised trial. Its sofosbuvir-plus-ribavirin regimen is now historical; the study demonstrated that antiviral therapy can improve HCV-associated cryoglobulinaemic vasculitis but does not define today's regimen.[13]

Modern evidence separates three outcomes: sustained virological response, clinical vasculitis response and immunological or clonal response. They may diverge. Current HCV regimens therefore come from up-to-date regional HCV guidance, while GISC consensus informs rituximab and severe-disease decisions in a field where high-quality comparative trials remain limited.[4][7][8]

The examiner asks: HCV RNA is undetectable, so is the vasculitis cured?

No. Sustained virological response is the essential first objective, but symptoms, cryoglobulins and pathogenic B-cell clones can persist or relapse. Reassess organ activity and treat the remaining disease according to severity.

[4] [6]

Find the cause, treat the cause — DAAs for HCV, rituximab for the refractory, plasma exchange for the catastrophic. And handle the tube at 37°C, or you will never make the diagnosis at all.[1][6]

[1] [2] [4] [8] [9]

Exam Application Bank (NEET-PG / INICET)

One-line answer

Cryoglobulinaemia is reversible cold precipitation of circulating immunoglobulins. Type I is monoclonal and predominantly occlusive; Types II and III are mixed rheumatoid-factor immune complexes that usually produce low-C4 small-vessel vasculitis. Confirm it with exact warm specimen handling, identify the cause, and treat by type and severity.[1][9]

Worked stems

Stem 1 — Purpura, neuropathy and urinary blood. Name the likely type, give the warm-sample instruction exactly, and list the infection, autoimmune and clonal searches.[1][9]

Stem 2 — Visual blurring, mucosal bleeding and a monoclonal protein. Recognise Type I hyperviscosity, arrange urgent plasma exchange and involve haematology for clone-directed therapy.[1][12]

Stem 3 — HCV RNA is undetectable but purpura returns. Do not call the vasculitis cured; reassess organ activity and a persistent B-cell process.[4][6]

[4] [8] [11]

References

1. [1]Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia Nat Rev Dis Primers, 2018.PMID 30072738
2. [2]Retamozo S, Quartuccio L, Ramos-Casals M Cryoglobulinemia Med Clin (Barc), 2022.PMID 35216803
3. [3]Ferri C, Zignego AL, Pileri SA Cryoglobulins J Clin Pathol, 2002.PMID 11825916
4. [4]Danishwar M, Jamil Z, Khan S, et al. Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure J Clin Med, 2022.PMID 35207257
5. [5]Passerini M, Schiavini M, Magni CF, et al. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience Eur J Gastroenterol Hepatol, 2018.PMID 30138160
6. [6]Pozzato G, Mazzaro C, Artemova M, et al. Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses Br J Haematol, 2020.PMID 32790920
7. [7]Quartuccio L, Bortoluzzi A, Scirè CA, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC) Clin Rheumatol, 2023.PMID 36169798
8. [8]Galli M, Monti G, Marson P, et al. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome Autoimmun Rev, 2019.PMID 31181326
9. [9]Sargur R, White P, Egner W Cryoglobulin evaluation: best practice? Ann Clin Biochem, 2010.PMID 20040797
10. [10]Zhang LL, Cao XX, Shen KN, et al. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients Ann Hematol, 2020.PMID 32535708
11. [11]Petersen T, Riviere S, Malbos S, et al. Subclasses of Monoclonal (Type I) Immunoglobulin G Cryoglobulins: Report on Two Distinct Cases with Myeloma Clin Lab, 2018.PMID 29739081
12. [12]Dammacco F, Lauletta G, Vacca A The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements Clin Exp Med, 2023.PMID 35348938
13. [13]Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study Ann Rheum Dis, 2016.PMID 26567178